Fenofibrate And Microvascular Events in Type 1 Diabetes (FAME 1) Trial

糖尿病是导致成年人失明的最常见原因之一。视力丧失是糖尿病最令人畏惧的并发症，这是不可逆转的。一种名为非诺贝特的降血脂药物在澳大利亚上市，已被证明可以将2型糖尿病患者的眼睛损伤减少35%-40%，并在1型糖尿病动物模型中预防眼睛损伤。这项研究将评估非诺贝特在450名患有早期糖尿病眼损伤的成人1型糖尿病患者中的潜在益处。

Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.